Margarita Romanenko, PhD, University of Minnesota, Minneapolis, MN, discusses potential future applications of oncolytic adenoviral vectors. Currently approved vector-based COVID-19 vaccines utilize adenoviral vector technology of varying serotypes, including adenovirus serotype 6 (Ad6). Dr Romanenko anticipates that therapeutics based on a range of adenovirus serotypes will be developed in the future and highlights this technology’s promise given the oncolytic potential and capacity for gene insertion associated with oncolytic adenoviral vectors. This interview took place during the American Society for Cell & Gene Therapy 24th Annual Meeting 2021.

свернуть